Literature DB >> 15273111

Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Dan Turner1, Bluma Brenner, Daniela Moisi, Mervi Detorio, Raymond Cesaire, Takashi Kurimura, Haruyo Mori, Max Essex, Shlomo Maayan, Mark A Wainberg.   

Abstract

We have compared nucleotide substitutions and polymorphisms at codons known to confer drug resistance in subtype B strains of human immunodeficiency virus type 1 (HIV-1) with similar substitutions in viruses of other subtypes. Genotypic analysis was performed on viruses from untreated individuals. Nucleotide and amino acid diversity at resistance sites was compared with a consensus subtype B reference virus. Among patients with non-subtype B infections, polymorphisms relative to subtype B were observed at codon 10 in protease (PR). These included silent substitutions (CTC-->CTT, CTA, TTA) and an amino acid mutation, L10I. Subtype A viruses possessed a V179I substitution in reverse transcriptase (RT). Subtype G viruses were identified by silent substitutions at codon 181 in RT (TAT-->TAC). Similarly, subtype A/G viruses were identified by a substitution at position 67 in RT (GAC-->GAT). Subtype C was distinguished by silent substitutions at codons 106 (GTA-->GTG) and 219 (AAA-->AAG) in RT and codon 48 (GGG-->GGA) in PR. Variations relative to subtype B were seen at RT position 215 (ACC-->ACT) for subtypes A and A/E. These substitutions and polymorphisms reflect different patterns of codon usage among viruses of different subtypes. However, the existence of different subtypes may only rarely affect patterns of drug resistance-associated mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273111      PMCID: PMC478480          DOI: 10.1128/AAC.48.8.2993-2998.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D.

Authors:  A Alaeus; K Lidman; A Björkman; J Giesecke; J Albert
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

2.  HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses circulating among injecting drug users.

Authors:  M M Thomson; E Delgado; N Manjón; A Ocampo; M L Villahermosa; A Mariño; I Herrero; M T Cuevas; E Vázquez-de Parga; L Pérez-Alvarez; L Medrano; J A Taboada; R Nájera
Journal:  AIDS       Date:  2001-03-09       Impact factor: 4.177

3.  World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Authors:  P R Harrigan; J S Montaner; S A Wegner; W Verbiest; V Miller; R Wood; B A Larder
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

4.  Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

Authors:  Christopher S Alexander; Valentina Montessori; Brian Wynhoven; Winnie Dong; Keith Chan; Michael V O'Shaughnessy; Theresa Mo; Magda Piaseczny; Julio S G Montaner; P Richard Harrigan
Journal:  Antivir Ther       Date:  2002-03

5.  Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.

Authors:  M J Todd; I Luque; A Velázquez-Campoy; E Freire
Journal:  Biochemistry       Date:  2000-10-03       Impact factor: 3.162

6.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

7.  Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Authors:  H Salomon; M A Wainberg; B Brenner; Y Quan; D Rouleau; P Coté; R LeBlanc; E Lefebvre; B Spira; C Tsoukas; R P Sekaly; B Conway; D Mayers; J P Routy
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

8.  Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.

Authors:  A J Frater; A Beardall; K Ariyoshi; D Churchill; S Galpin; J R Clarke; J N Weber; M O McClure
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

9.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

10.  Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Authors:  Hugues Loemba; Bluma Brenner; Michael A Parniak; Shlomo Ma'ayan; Bonnie Spira; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  9 in total

Review 1.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

2.  Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

Authors:  Maria Mercedes Santoro; Massimo Ciccozzi; Claudia Alteri; Stefania Montieri; Ivailo Alexiev; Iordanka Dimova; Francesca Ceccherini-Silberstein; Danail Beshkov; Giovanni Rezza; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

3.  An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Authors:  Kristof Theys; Pieter J K Libin; Kristel Van Laethem; Ana B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

Authors:  Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman
Journal:  Clin Infect Dis       Date:  2015-02-13       Impact factor: 9.079

5.  Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.

Authors:  Dilek Alpsar; Ali Agacfidan; Nadine Lübke; Jens Verheyen; Haluk Eraksoy; Atahan Cağatay; Emel Bozkaya; Rolf Kaiser; Baki Akgül
Journal:  Med Microbiol Immunol       Date:  2013-01-08       Impact factor: 3.402

6.  In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

Authors:  Meizhen Feng; Deping Wang; Jay A Grobler; Daria J Hazuda; Michael D Miller; Ming-Tain Lai
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

7.  Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.

Authors:  Vici Varghese; Elijah Wang; Farbod Babrzadeh; Michael H Bachmann; Rajin Shahriar; Tommy Liu; Svetlana Jean M Mappala; Baback Gharizadeh; W Jeffrey Fessel; David Katzenstein; Seble Kassaye; Robert W Shafer
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

8.  Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.

Authors:  P Richard Harrigan; Chih-Wei Sheen; Vikram S Gill; Brian Wynhoven; Erin Hudson; Viviane D Lima; Pierre Lecocq; Rosalia Aguirre; Art F Y Poon; Nicolas Sluis-Cremer
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

9.  APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants.

Authors:  Richa Dwivedi; Youya Wang; Christopher Kline; Douglas K Fischer; Zandrea Ambrose
Journal:  Front Virol       Date:  2022-07-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.